Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what steps he is taking to ensure that women suffering from metastatic HER2 breast cancer receive (a) the Kadcyla form of Trastuzumab emtansine and (b) other required medication.

Improving the availability and use of effective medicines for all cancers, including breast cancer, is a key priority.

The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations on whether selected drugs and treatments represent a clinically and cost effective use of National Health Service resources. Commissioners are legally required to fund drugs and treatments for the treatment of metastatic HER2 breast cancer recommended in NICE technology appraisal guidance within three months of its final guidance being issued.

NICE technology appraisal guidance, published in December 2015, does not recommend trastuzumab emtansine (Kadcyla) for the treatment of HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane. In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund new medicines based on an assessment of the available evidence.

Trastuzumab emtansine continues to be available to patients in England through the Cancer Drugs Fund, subject to certain clinical criteria.

The new arrangements for the Fund, which came into effect on 29 July 2016, will ensure that the most promising and innovative medicines get to patients as quickly as possible. In particular, NICE will issue draft guidance on new cancer drugs or significant new licence indications before they have received marketing approval in the United Kingdom. Any drug that receives a positive draft recommendation would then be funded from the point of licence.